Johnson & Johnson (JNJ.N) said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of bladder cancer as the drug did not show superior benefits compared to chemoradiation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,